The current project evaluated the effect of the clinical-stage PARP inhibitors olaparib, veliparib, rucaparib, talazoparib, and niraparib in oxidatively stressed cultured epithelial cells and monocytes in vitro and also assessed the efficacy of two selected inhibitors, olaparib and rucaparib in a murine model of ALI in vivo. This evidence concerns the gene PARP1 and acute respiratory distress syndrome.